rotid body (CB) chemoreceptor cells detect physiological levels of hypoxia and generate a hyperventilation, homeostatic in nature, aimed to minimize the deleterious effects of hypoxia. Intimate mechanisms involved in oxygen sensing in chemoreceptor cells remain largely unknown, but reactive oxygen species (ROS) had been proposed as mediators of this process. We have determined glutathione levels and calculated glutathione redox potential (E GSH; indicator of the general redox environment of cells) in rat diaphragms incubated in the presence of oxidizing agents of two types: nonpermeating and permeating through cell membranes; in the latter group, unspecific oxidants and inhibitors of ROS-disposing enzymes were used. Selected concentrations of oxidizing agents were tested for their ability to modify the normoxic and hypoxic activity of chemoreceptor cells measured in vitro as their rate of release of neurotransmitters. Results evidence variable relationships between E GSH and the activity of chemoreceptor cells. The independence of chemoreceptor cell activity from the EGSH would imply that the ability of the CB to play its homeostatic role is largely preserved in any pathological or toxicological contingency causing oxidative stress. Consistent with this suggestion, it was also found that CB-mediated hypoxic hyperventilation was not altered by treatment of intact animals with agents that markedly decreased the EGSH in all tissues assayed. oxygen sensing; carotid body; reactive oxygen species; hypoxia; reduced glutathione, oxidized glutathione; catecholamine; ventilation CAROTID BODIES (CB) ARE ARTERIAL chemoreceptors that sense arterial blood PO 2 and are activated by hypoxia. Hypoxic CB activation promotes hyperventilation aimed to normalize blood PO 2 ; this response confers to CB function an adaptive significance (15). Cellular and molecular mechanisms involved in hypoxic activation of the CB chemoreceptor cells are not completely understood. According to the membrane model for O 2 chemoreception, minimal elementary steps in hypoxic activation include O 2 sensing, inhibition of specific plasma membrane K ϩ channels, cell depolarization, activation of voltageoperated Ca 2ϩ channels, and neurotransmitter release (14). Released neurotransmitters would increase action potential frequency in the carotid sinus nerve, which, through its projection into the brain stem, triggers hyperventilation.
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Some steps in this transduction cascade for the hypoxic stimulus are conflictive, discrepancies being linked, in some instances, to species differences. For example, there are welldefined species differences in the identity of O 2 -sensitive K ϩ channels (5, 31) and in the chemical nature of the so-called primary neurotransmitters (13, 24, 66) . However, there are other steps in which uncertainties are more general, in the sense that they would refer to chemoreceptor cells of all species and also shared by other O 2 -sensing cells like pulmonary artery smooth muscle or neonatal adrenomedullary cells. This is the case for the nature of the O 2 sensor and for the mechanisms coupling the O 2 sensor to O 2 -sensitive K ϩ channels. Proposals for O 2 sensors are multiple, including a NADPH-oxidase, an unidentified plasma membrane hemoprotein, and some (or multiple) mitochondrial components of the respiratory chain (18) . Reactive oxygen species (ROS) have raised great interest as messengers coupling the O 2 sensor to K ϩ channels in chemoreceptor, pulmonary artery smooth muscle, and neonatal adrenomedullary cells. The general schema for the participation of ROS is that they would alter the general redox status of cells, best identified by the GSH/GSSG ratio (or by glutathione redox potential, E GSH ), with the obligated parallel ϪSH/ϪSϪSϪ ratio change in the K ϩ channel protein, and change in the kinetic properties of oxygen-sensitive K ϩ channels (1, 7, 51, 57, 58) . The general problem with proposals linking ROS to oxygen-sensing is that they are diametrically opposed: some authors suggesting that hypoxia decreases ROS production (1, 51, 58) and others suggesting that the signal generated by hypoxia is an increase in ROS (7, 39, 56, 57) .
Our hypothesis is that even if hypoxia causes a general shift in cytosolic redox to a more reduced or oxidized status, it is not the link between hypoxia and the plasma membrane K ϩ channel inhibition. In previous studies we have shown that chemoreceptor cell responses were not affected by reducing agents (16, 45) . In the present work we have tested the capacity of a diverse group of oxidant agents to modify CB chemoreceptor cell activity, assessed by their ability to alter the normoxic and hypoxic release of catecholamines (CA), one of the most abundant chemoreceptor cell neurotransmitters. We have chosen the release of CA as an index of chemoreceptor cell activity because a tight correlation between CA release and intensity of stimulation has been well documented (10, 33, 43) . Oxidant agents studied pertained to three different functional groups: 1) p-chloro-mercuri-phenyl-sulfonate (PCMBS) and 6,6Ј-dithiodinicotinic acid (DTNA) are nonpermeating through plasma cell membranes, and therefore their actions would be restricted to the extracellular face of the plasma membrane; 2) GSSG, 2,2Ј-dithiodipyridine (DTDP), and diamide (Dia) are permeating to cell membranes, and therefore they would cause oxidations both extracellularly and intracellularly; and 3) buthionine sulfoximine (BSO, inhibitor of the glutathione synthesis), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, inhibitor of glutathione reductase), and 3-aminotriazole (AT, inhibitor of catalase); inhibitors of ROS disposal enzymes would cause primarily (or exclusively) intracellular oxidation. Drug concentrations were selected on the basis of their capacity to alter E GSH in rat diaphragm, due to the small size of CBs. We found that while all oxidant agents permeating to cell membranes decreased the E GSH , only some of them were able to modify the release of CA from chemoreceptor cells. Nonpermeating agents did not alter E GSH or the activity of chemoreceptor cells. We conclude that the activity of chemoreceptor cells, whether in normoxia or in hypoxia, is independent of the general redox status of cells. This conclusion was supported by the additional observation that BSO-induced oxidized status in rabbits and rats did not alter their normoxic, hypoxic, or hypercapnic ventilation.
MATERIALS AND METHODS

Surgical procedures.
To remove the diaphragm, adult Wistar rats of both sexes (250 -300 g body wt) were anesthetized with pentobarbital sodium (60 mg/kg ip) dissolved in physiological saline. An ample incision in the abdomen allowed the retraction of the abdominal viscera to visualize the diaphragm, which was cut from its insertion to the ribs and placed in a lucite chamber filled with ice-cold 100% O 2-saturated Tyrode solution (in mM: 140 NaCl, 5 KCl, 2 CaCl2, 1.1 MgCl 2, 5.5. glucose, and 10 HEPES; pH 7.40 with 1 N NaOH). After removal of the phrenic tendon and small pieces of fat under a dissecting microscope, the diaphragm was cut into four quadrants, each constituting an experimental sample.
To remove the CB, adult New Zealand White rabbits were similarly anesthetized with pentobarbital sodium (40 mg/kg) administered through the lateral vein of the ear. A longitudinal incision was made in the ventral surface of the neck, and the carotid arteries were located and dissected ϳ1 cm proximally and distally to the carotid sinus region. A block of tissue, containing the carotid bifurcation up to the level of the hypoglossal nerve, was removed and placed in the Tyrode solution-filled lucite chamber. With the aid of a dissecting microscope, the CB was identified, freed of connective tissue, and individualized from the arterial vessels. Young rabbits were similarly anesthetized, and liver, brain, and diaphragm tissue was collected and frozen to Ϫ80°C until used.
Animals were killed by an intracardiac overdose of pentobarbital sodium. The Institutional Committee of the University of Valladolid for Animal Care and Use approved the protocols.
Measurements of glutathione. Each diaphragm sample was placed in glass scintillation vials containing 10 ml bicarbonate-buffered Tyrode solution (composition as above except for the substitution of 24 mM NaCl with 24 mM of NaHCO 3) and kept in a metabolic shaker bath at 37°C. All pieces were initially incubated during 30 min in Tyrode-bicarbonate solution equilibrated with 21% O 2-5% CO2 to achieve uniformity by allowing the tissue to recover from the dissection stress (36) . After this initial incubation, solutions were renewed every 10 min for up to 40 min, and in some instances for 80 min. Experimental solutions contained different drugs at concentrations specified in RESULTS. Incubating vials were continuously bubbled with 21% O 2-5% CO2 (balance N2) saturated with water vapor. Incubation time in control 21% O 2-equilibrated solutions does not modify GSH or GSSG levels for up to 80 min (17) . At the end of the incubation the diaphragm pieces were placed during 5 min in new glass vials containing 10 ml ice-cold Tyrode solution. Tissues were dry-blotted on filter paper, weighed, and placed in Eppendorf tubes containing a solution of 5-sulfosalicylic acid (SSA) at 5% and 0.25 mM EDTA; SSA solution volume was adjusted to ϫ5 tissue weight. Tissues were stored at Ϫ80°C until assay or immediately glass-to-glass homogenized at 0 -4°C and centrifuged in a microfuge (4°C, 10 min), and the supernatant was used to measure GSH/GSSG.
Measurements of GSH and GSSG were made as previously described in detail (17) . In brief, spontaneous reduction of 5,5Ј-dithiobis-(2-nitrobenzoic acid) (DTNB) by GSH generates 5-thio-2-nitrobenzoic acid (peak absorbance at 412 nm) and GSSG. The GSSG formed is back reduced enzymatically to GSH by glutathione reductase coupled to NADPH oxidation. This enzymatic step makes the assay highly specific, and cycling renders it very sensitive (10 Ϫ10 mol/assay). Reactant concentrations (DTNB, NADPH, and glutathione reductase) are selected to obtain a linear rate of color formation during 2-3 min. The slope of the linear color formation (⌬ absorbance/⌬ time, min) is directly proportional to the amount of total glutathione in the sample. Preparing assays with different amounts of GSH yields a fan of lines with different slopes. The plot of the slopes of these lines as a function of the GSH used is also linear and defines the standard curve. This standard curve allows to define the concentrations of total glutathione (GSt ϭ GSH ϩ GSSG) in the problem samples by interpolation. To specifically determine GSSG, the GSH present in the tissue supernatants is destroyed with 2-vinylpyridine and later assayed as before, except for the use of higher sample size due to the usually lower concentration of GSSG in comparison to GSH. Unless there are limitations of tissue supernatant, both standard and problem samples are assayed in triplicate. In the problem samples, the concentration of GSH is obtained as the difference G St Ϫ GSSG. The assay mixture has been detailed before (17) . From GSH and GSSG levels, the glutathione redox potential (EGSH) was calculated using the 20 Ci/mmol), 100 M 6-methyl-tetrahydropterine, and 1 mM ascorbic acid, cofactors for tyrosine hydroxylase and dopamine-␤-hydroxylase, respectively (10); usually, eight CBs were incubated simultaneously. After the labeling period, the CB were individualized in glass scintillation vials kept at 37°C in the metabolic shaker and containing 4 ml precursor-free bicarbonatebuffered Tyrode solution. Solutions were continuously bubbled with 20% O 2-5% CO2-balance N2 saturated with water vapor. Application of hypoxic stimulus consisted of an incubation of 10 min of duration in a solution equilibrated with a gas mixture containing 7% O2-5% CO2-balance N2 (also saturated with water vapor). During the initial first hour, solutions were collected every 20 min and discarded. Thereafter, solutions were collected every 10 min and saved for analysis in their [ 3 H]CA content. In some experiments, CBs were also stimulated by incubation for 10 min with a depolarizing solution containing 35 mM K ϩ (identical concentration of NaCl was removed to maintain osmotic balance). Incubating solutions were collected in glass scintillation vials, and, to prevent degradation of the [ 3 H]CA released, they were acidified to pH 3 by the addition of glacial acetic acid and 1 mM ascorbic acid and maintained at 4°C. At the end of the experiments, CB tissues were homogenized (0.4 N perchloric acid; 300 l) and centrifuged in a microfuge (10 min; 4°C), and the supernatant was stored for [ 3 H]CA analysis. Whole body plethysmographic recordings in rabbits and rats. Ventilation was measured in conscious, freely moving young rabbits (700 -900 g) and adult rats by whole body plethysmography. The system (Emka Technologies, Paris, France) consisted of 5-liter methacrylate chambers continuously fluxed (2 l/min); the temperature inside the chamber was within the thermoneutral range (22-24°C). Animals were placed in the plethysmographic chamber flushed with room air for an initial period of ϳ30 min until they adapted to the chamber ambient and acquired a standard resting behavior. Thereafter, we initiated the recording while flushing the pletysmopgraphic chamber with different gas mixtures (see RESULTS). Each recording period lasted 10 min. The plethysmographic system allows recording pressure fluctuations within the chamber with a high gain differential transducer. Ideally, the frequency of pressure fluctuations would correspond to breathing frequency (breaths/min), but there are spurious fluctuations due to animal movements that were electronically rejected. The amplitude of the oscillations is proportionally related to the tidal volume (VT, in ml); a calibration of the system by injecting into the chamber 0.2 and 0.5 ml of air allows software computing of VT. Pressure signal was fed into a computer for visualization, storage, and offline analysis with Emka software. Specific treatments of animals before the plethysmographic study are described in RESULTS.
Statistical analysis. Means Ϯ SE of the values obtained in replicated experiments were calculated and compared using a two-tailed Student's t-test for unpaired data. For multiple comparisons, i.e., when we had a control group and two or more experimental groups, we used an analysis of variance to test for statistical significance among differences. It was considered that the data were significantly different if the P value obtained was lower than 0.05.
RESULTS
Effects of oxidizing agents on rat diaphragm E GSH and rabbit CB chemoreceptor cell function.
With minor variations from experiment to experiment, GSH and GSSG levels in control tissues were, respectively, in the range between 0.4 -0.5 and 0.02-0.025 g/g wet tissue. In text and figures we refer exclusively to E GSH . Every drug tested had its correspondent control values obtained simultaneously. Figure 1 shows the effects of oxidizing agents on E GSH in the rat diaphragm from two groups of oxidizing agents: nonpermeating through plasma cell membranes like PCMBS (5 and 50 M) and DTNA (50, 100, and 200 M) (Fig. 1A) , and permeating to cell membranes (Fig. 1B) . In this last category of drugs we tested DTDP, Dia, and GSSG. PCMBS is strongly ionized at physiological pH and therefore would not penetrate inside the cells. It reacts with extracellular free ϪSH groups of cysteines forming additional compounds with plasma membrane proteins. DTNA, which is also nonpermeating through cell membranes due to its doubleionized group, would react with a pair of ϪSH groups forming a disulfide bond ϪSϪSϪ and release two molecules of thiopyridone. Therefore it would be expected not to alter E GSH , as indeed was the case. DTDP, as DTNA, is formed by two pyridine rings linked by a disulfide bond, but it lacks the carboxylic groups of DTNA, and therefore it permeates through cell membranes. Therefore DTDP can oxidize free ϪSH in an exchange reaction with its disulfide group both extracellularly and intracellularly; its reaction with GSH will generate GSSG. Figure 1B shows that 10 M DTDP did not modify E GSH (Ϫ179.6 Ϯ 1.0 mV), but 50 and 100 M caused a significant decrease in GSH and increase in GSSG with the result of a marked decrease in E GSH (Ϫ162 Ϯ 1.2 and Ϫ158 Ϯ 0.4 mV, respectively).
Diamide is a commonly used oxidizing agent that reacts rapidly with sulfhydryl groups. It is a compound with a double bond between two adjacent N atoms, each N bonded to a carbonyl group. The double bond disappears easily on acceptance of protons and electrons from sulfhydryl groups including GSH in the cell interior, and thereby Dia should cause a decrease in E GSH (27) . Figure 1B shows that Dia caused a dose-dependent decrease in E GSH that was statistically signif- Most cell systems possess active GSSG export mechanisms capable of extruding GSSG in any situation causing oxidative status (46, 47) . Although the literature on cellular GSSG uptake is scarce, it is well documented that GSSG is taken by proximal tubule kidney cells with very limited reduction to GSH, with the net effect of generating an intense oxidative status in the cell interior (54) . Following this finding, we tested whether incubation of diaphragm with GSSG will cause a change in E GSH . We found that indeed incubation of diaphragms with 0.25 and 1 mM caused a decrease and in E GSH that was highly significant (Ϫ155.5 Ϯ 1.2 mV) with the highest concentration (Fig. 1B) . Figure 2B shows the effect of 50 M PCMBS on the release induced by a moderate hypoxic stimulus (10 min; 7% O 2 -equilibrated solutions; PO 2 Ϸ46 mmHg). This intermediate intensity of hypoxic stimulation was chosen to facilitate uncovering of potential positive and negative modulation of the hypoxic response by the oxidizing agents. Very minor changes in the time course of the hypoxic response were noticed (Fig. 2B) , and the magnitude of the hypoxic response (equivalent to the area under the curves) was identical in control and PCMBS-incubated CBs (Fig. 2C) . DTNA was tested on normoxic and hypoxic release of [ 3 H]CA at concentrations of 100 and 200 M. Concentrations tested did not significantly alter normoxic (not shown) or hypoxic release (Fig. 2D) . Figure 3 shows the effects of oxidizing agents permeant to cell membranes (DTDP, Dia, and GSSG) on the normoxic and hypoxic release of [ 3 H]CA from CB chemoreceptor cells. Figure 3 (top) shows that 100 M DTDP activated the normoxic release and potentiated the release induced by the hypoxic stimulus. Dia (Fig. 3, middle) produced a dose-dependent (50 -400 M) increase in the normoxic release of [ 3 H]CA, but none of the concentrations tested altered the release induced by the hypoxic stimulus. GSSG (Fig. 3, bottom) at 0.25 and 1 mM did not alter the normoxic or the hypoxic release of [ 3 H]CA from chemoreceptor cells. In sum, data presented in this section evidence a lack of correlation between the oxidizing power of the agents used and the activity of chemoreceptor cells.
Effects on diaphragm E GSH and CB chemoreceptor function produced by inhibitors of enzymes involved in ROS disposal. Carmustine (BCNU) is an inhibitor of glutathione reductase, and therefore it tends to decrease GSH levels according to their rate of oxidation; in parallel it also tends to increase GSSG levels. Because of the location of glutathione reductase in the cell interior, BCNU is exclusively an intracellular oxidant. BCNU was tested (40 min) at concentrations of 10, 30, 100, 500, and 1,000 M, and it was found that the two highest concentrations very significantly decreased E GSH on rat diaphragm (Fig. 4A) . The same range of BCNU concentrations did not modify the time course or the magnitude of the normoxic (Fig. 4B) . Effects of BCNU on the release of [ 3 H]CA induced by hypoxia were only tested at the two highest concentrations, and it was found that 500 M was not effective to alter the hypoxic response of chemoreceptor cells, but 1,000 M increased the hypoxic release (Fig. 4C) .
BSO in the micromolar range (26) is an inhibitor of the ␥-glutamyl cycle responsible for the synthesis of GSH. As a consequence, it depletes GSH and produces an oxidized status in the cells. Figure 5A shows the effect of 40 min of incubation with 100 and 250 M BSO on the E GSH . This period of incubation caused a small nonsignificant tendency for E GSH to decrease. Doubling the incubation time with the highest concentration, BSO produced a moderate but significant decrease on E GSH . Figure 5B shows that 250 M BSO applied during 80 min did not modify the time course or magnitude of normoxic (Fig. 5C) . A situation comparable to that encountered with BSO was observed with the use of AT (an inhibitor of catalase). Incubation of tissues with AT (10 mM) during 40 min did not alter diaphragm E GSH , but 80 min of incubation decreased it very significantly (Ϫ163.0 Ϯ 3.1 mV; Figure 6A ). Incubation of CBs with 10 mM AT in normoxia caused a significant release from minute 20 to 50 of drug application, tending thereafter to recover control release levels (Fig. 6B) . However, AT did not alter the release induced by the hypoxic stimulus (Fig. 6C ). This group of findings indicates once again a lack of correlation between the oxidizing power of the agents used and the activity of chemoreceptor cells.
Effects of in vivo treatment with BSO on redox status and ventilation. The preceding in vitro experiments would indicate that there is not a fixed relationship between the redox status and the release of [
3 H]CA from chemoreceptor cells. Therefore we tested the effect of a generalized oxidized status on the CB-mediated hypoxic ventilation in vivo. Since to our knowledge there are no studies on the distribution of BSO after intraperitoneal injections, we performed trial experiments using groups of three rabbits treated with different doses of BSO administered as a single dose (2 mmol/kg, 20 h before exper- Experimental protocol to test the effects of the drugs on the normoxic release are also shown. In the protocol to test the effects of the drugs on the hypoxic release, drugs were present in the incubating solutions the 30-min period before and the 10 min of hypoxic stimulation. In control CBs, hypoxic stimulus was applied in a drug-free solution. DTDP was tested only at the concentration of 100 M and produced a clear increase of the normoxic release and a comparable augmentation on the low PO2-induced release. Dia at concentrations of 50 to 400 M augmented with certain dose-dependency the normoxic release but lacked any effect of the low PO2-induced release. GSSG did not affect normoxic or hypoxic release of [ 3 H]CA (standard errors were omitted in the normoxic release curves for clarity). In all instances, data are means Ϯ SE of 6 -8 individual values. **P Ͻ 0.01. iments), as two doses of 2 mmol/kg (20 and 6 h before experiments), and as two doses of 3 mmol/kg (20 and 6 h before experiments). There was a dose-dependent decrease on E GSH from tissues tested. We chose the largest dose because it produced a very significant decrease in E GSH. Figure 7 , A-C, shows that BSO-treated rabbits had lower GSH levels and lower E GSH in all studied tissues than saline-treated control rabbits. Figure 8 shows that in BSO-treated rabbits, neither normoxic, hypoxic, nor hypercapnic ventilatory frequency (Fig.  8A ), tidal volume (Fig. 8B) , nor minute ventilation (Fig. 8C) was significantly altered when compared with control animals.
In an additional group of adult rats we measured the same parameters after BSO treatment. In this species the lowest dose tested in the rabbit produced a significant decrease on tissue E GSH and therefore was our dose of choice. As shown in Table 1 and Fig. 7 , a multisystemic decrease in redox potential did not alter normoxic, hypoxic, or hypercapnic ventilation in these species. Thus, as was the case in the in vitro experiments, findings obtained in vivo evidence that an oxidized status of the entire animal as assessed in three different tissues does not affect CB chemoreceptor O 2 sensing, because hypoxic ventilatory responses are entirely mediated by the CB (15) .
DISCUSSION
The present study's aim was to underscore any possible relationship between the general redox status of chemoreceptor cells and their level of activity, both in normoxia and hypoxia. We have found that several agents, chemically different and with different oxidizing mechanisms, exhibited unpredictable actions on the activity of chemoreceptor cells, assessed as their normoxic or hypoxic release of CA. For example, DTDP, Dia, and GSSG, used at concentrations capable of producing a marked and comparable oxidizing effect, augmented (DTDP and Dia) or had no effect (GSSG) on the normoxic [ 3 H]CA release from the CB chemoreceptor cells, and only DTDP increased the release response elicited by hypoxia. The three inhibitors of ROS disposal enzymes used caused a comparable oxidized state and generated similarly variable effects on chemoreceptor cell function. Among them, only AT caused a modest augmentation of normoxic release, and only BCNU caused an augmentation of the release response elicited by hypoxia. These findings would indicate that the activation of chemoreceptor cells (i.e., activation of the release of neurotransmitters) produced by some of the tested agents is not the result of activation of the hypoxic physiological transduction cascade; instead, their activation of the release of neurotransmitters would result from their direct action on the exocytotic machinery.
The small size of the CB (Ϸ400 g in the rabbit) has dictated the experimental design followed in the present work. We have used a different tissue from the CB to assess the oxidizing power of agents under study to select the concentrations to be tested on the CB function. It might be argued that this experimental design poses a certain degree of uncertainty in the interpretation of our findings. However, the uncertainties have been minimized by at least two reasons. First, the selected tissue, diaphragm, contains very similar levels of GSH and GSSG to those in the calf CB (45); therefore, based on mass action laws, permeating nonspecific oxidizing agents should be expected to have a comparable variation of E GSH in both tissues. Second, concentrations used of inhibitors of ROS disposal enzymes were chosen well above their K i , and in fact, their effectiveness to decrease E GSH in diaphragm demonstrates the correctness of the dose used. For example, the K i of BSO for ␥-glutamylcysteine synthetase is ϳ7.5 M in both rat kidney and liver (23, 32) , and it should be expected that, at 100 and 250 M, the enzyme is fully inhibited; thus with these BSO concentrations the time-dependent decrease of GSH levels is directly related to its turnover. Similarly, the K i of BCNU for glutathione reductase is in the range of 15 M (48); the wide range of BCNU concentration used would assure a full inhibition of the enzyme, and the decrease of E GSH would be related to the rate of hydrogen peroxide generation and elimination by the GSH/GSSG system. The K i of AT for catalase is very high (ϳ5 mM; 53), and the concentration used in our experiments (10 mM) should inhibit the enzyme above 70%, and indeed it produced a significant decrease on diaphragm E GSH . We have chosen to evaluate concentrations of drugs tested because those used in published studies are very variable. For example, we have used DTDP concentrations from 10, 50, and 100 M and have avoided the use of concentrations in the high micromolar or millimolar range, as used by many authors in several biological preparations (8, 22, 28) , because the two highest concentrations used caused a very significant decrease in the diaphragm E GSH , and therefore they would be sufficient to activate the hypoxic transduction cascade if the proposal of Chandel and Schumacker (7) happens to be correct. A similar situation is encountered with diamide (64) and the rest of the drugs studied. Finally, we want to state that the redox status of cells does not need to vary by great percentages to trigger changes in the cell functionality. Schafer and Buettner (46) estimate that a 12% change in tissue E GSH is enough to push proliferating cells into apoptosis. In our study we have chosen concentrations of oxidants that cause a change on E GSH between 6% and 15%. These changes are probably smaller than those encountered in any tissue in anoxia, but the CB responds to hypoxias of mild, moderate, and high intensities. Therefore, alterations produced by the oxidant agents on E GSH would be mimicking different levels of hypoxia and generating accordingly release responses in chemoreceptor cells. In other words, the changes in E GSH should suffice to activate chemoreceptor cells at different levels if a link between redox status and transduction exists. The lack of effect of the first group of agents tested, i.e., nonpermeating oxidizing agents, on E GSH was the expected. However, their lack of effect on the normoxic and hypoxic activity of chemoreceptor cells was unexpected, because there are at least two reports in the CB literature describing actions of PCMBS. Thus, Lahiri (29) found that sulfhydryl reagents including PCMBS and N-ethylmaleimide irreversibly augmented the normoxic and hypoxic activity in the carotid sinus nerve, and Wyatt and Peers (63) found that PCMBS irreversibly inhibited Ca 2ϩ -dependent K ϩ channels in rat chemoreceptor cells. Although it would appear reasonable to link the findings of both studies to suggest that PCMBS is acting via chemoreceptor cells to increase the activity in the carotid sinus nerve, it might also be proposed that the action of PCMBS on the activity of the carotid sinus nerve is generated directly at the nerve endings because inhibition of Ca 2ϩ -dependent K ϩ channels does not generate cell depolarization or intracellular Ca 2ϩ transients in chemoreceptor cells (4) .
Comparison of findings with DTNA and DTDP are illustrative. They are chemically identical except for the absence in DTDP of two carboxyl groups, and therefore they have comparable redox potential (52) . The absence of carboxyl groups makes DTDP permeate through cell membranes, and this permeability produces a decrease in E GSH and activates chemoreceptor cells. Stated in a different manner, both agents would cause a similar oxidation of extracellular ϪSH groups but only DTDP, which penetrated into the cells, would alter chemoreceptor cell functionality. However, the activating effect of DTDP on chemoreceptor cells in normoxia and hypoxia does not appear to be linked to activation of the hypoxic transduction cascade (see Introduction); rather it might result from direct oxidation of some element of exocytotic machinery or to spurious, redox-unrelated effects. This interpretation is supported by our observations with Dia, which caused a comparable decrease in E GSH , activated chemoreceptor cells in normoxia, but not in hypoxia. In this context it is worth mentioning that Dia has variable effects on insulin release; with some secretagogues it promoted and with some others it did not affect insulin release (3) . It should also be mentioned that Dia inhibited hypoxic pulmonary and prostaglandin F 2␣ vasoconstriction (59), implying an effect nonspecifically linked to hypoxic response. Additionally, GSSG, also causing a decrease in E GSH , did not activate chemoreceptor cells either in normoxia or hypoxia. These variable findings would indicate that the actions of the oxidizing agents on chemoreceptor cells (and pulmonary artery smooth muscle cells) are not the result of oxidization of key molecular components in the hypoxic transduction cascade (e.g., oxygen-regulated K ϩ channels). The inhibitors of ROS disposing enzymes, BCNU, BSO, and AT, produced equally variable effects on chemoreceptor cells.
The interpretation given to our findings is not the only one possible. In fact, a counterinterpretation can be given, namely, that all oxidants activate chemoreceptor cells following the physiological hypoxia transduction cascade through their oxidizing action as proposed by Schumacker and coworkers (57) (see Introduction), but drug-specific oxidizing or spurious effects inhibit the exocytotic machinery, and thereby a null effect of the drug is observed in our experiments. This alternative interpretation seems unlikely because none of the oxidants tested inhibited the release in normoxia nor prevented the exocytotic release in hypoxia: it is extremely unlikely that several drugs (PCMBS, DTNA, GSSG, and BSO) inhibit the machinery of exocytosis to a degree that exactly cancels out the activation of the cells via the physiological pathway. In addition, it is well documented that oxidizing agents promote release of a variety of neurotransmitters via their oxidizing power as their actions were reverted by reducing agents. For example, Dia has been found to promote release of acetylcholine, dopamine, norepinephrine, GABA, and glutamate, but the concentrations of Dia required to promote the release in different preparations varied from 100 M to 13 mM (6, 55) . The same effects were observed for DTNB (an analog of DTNA), and again the range of concentrations varied enormously within preparations from 0.5 to 9 mM (62, 67). These quoted articles discuss the possible mechanisms of action centered in the exocytotic machinery, and indeed this is the interpretation we have given to our findings in previous paragraphs. Therefore we consider that we have made a judicious use of all agents tested limiting the doses used to concentrations that alter the E GSH in in vitro and in vivo experiments. Accordingly, present findings would allow us to state that 1) the oxidants tested acting through their oxidizing power do not activate the physiological hypoxia transduction cascade; 2) the variable effects of oxidizing agents on the release of CA from chemoreceptor cells are the result of spurious actions of the drugs, most likely reflecting their effect on some components of the exocytotic machinery; and 3) we cannot exclude that other cell constituents, different from exocytotic machinery itself, are targets for some oxidant agents; it could be via the functional alteration of these cell constituents that CA release is modified. In this regard, Winterbourn and Hampton (61) in a recent review indicate that plausible targets for ROS, and therefore oxidizing agents, would be enzymes having in their active centers cysteine residues or iron-sulfur clusters, or ion channels whose pore of selectivity/voltage-dependency domains contain cysteine residues (40) . Yet, the redox modification of any enzyme or channel in a given cell type, and the direction of the functional modification (activation or inhibition), would depend on factors such as diffusion of the oxidant to the target, the rate constant of the reaction between the oxidant, and the target and the potential competition between substrates susceptible of oxidation, as for example, GSH concentration in the cell microdomain where the target protein is located (61) . An additional comment in this regard is that in experiments in course (data not shown), we have found that hyperoxia (PO 2 Ϸ630 mmHg) that is known to cause oxidation in all tissues did indeed diminish the E GSH in the diaphragm and inhibited the release of CA from chemoreceptor cells.
Our last group of experiments in intact animals confirms that a general shift of the redox state of the cells does not constitute a key step in hypoxic activation of chemoreceptor cells. As shown in Fig. 7 and Table 1 , the treatment with BSO caused a generalized oxidized status that was more intense in liver and diaphragm, because BSO penetrates slowly the blood-brain barrier (9) . If as it has been proposed (7, 56, 57) a general cytosolic redox shift to an oxidized status is the link to hypoxic activation, then BSO treatment should produce hyperventilation when the rabbits and rats are at normal PO 2 and potentiate hyperventilation in hypoxia. However, this was not observed: normoxic and hypoxic (and hypercapnic) minute ventilation was not statistically different in BSO-treated and control rabbits and rats ( Fig. 8 and Table 1 ). Yet, it should be mentioned that BSO showed a tendency to modify the respiratory pattern, tending to decrease respiratory frequency and to increase tidal volume. Conversely, our in vivo experiments do not support the opposing model in which a redox switch to a more reduced state is the signal triggering chemoreceptor cell activation (1) . If this were the case, BSO-treated animals should hypoventilate in normoxia and exhibit a diminished hypoxic hyperventilation.
We consider that the findings of in vivo experiments might have profound physiological significance: the hypoxic transduction cascade in chemoreceptor cells, and consequently the hyperventilation induced by hypoxia, is preserved from any concurrent contingency that might cause an alteration of the general redox status of the animal. Or, in other words, the adaptive and homeostatic significance of the CB capacity to respond to hypoxia and to control ventilation seems to be maintained independently of the general redox status of animals. For example, in chronic obstructive pulmonary disease there is a well-documented overproduction of ROS (25, 42) , and hypoxic drive in these patients is proportional to the intensity of hypoxia produced by the illness (2, 50) ; in diabetes, whether in experimental animals or in humans, there is also an exaggerated production of ROS and a generalized oxidized status (30, 41) . Certainly, the CB-mediated hypoxic respiratory drive has been described to be impaired in diabetes (60) . However, when mostly centrally mediated hypercapnic drive has been studied in diabetes, it has also been found to be depressed (21, 34, 65) , implying that the depression is centrally mediated. Consistent with this notion, it has been reported that in diabetes, several neurotransmitter systems in the brain stem are altered (65) .
From the ongoing discussion, it might appear that we are denying any potential significance for ROS in the modulation of chemoreceptor cells (or pulmonary artery smooth muscle cells) activity in normoxia or hypoxia. Certainly, this is not our view. For example, He et al. (20) have shown that physiologically relevant levels of hypoxia increased NADPH oxidasederived ROS and obtained evidence that these ROS act as second messengers, modulating negatively the response elicited by hypoxia. The present findings, in conjunction with the opinion expressed by other authors (11) , would suggest that local levels of ROS are the true regulating signals. We are envisioning these local concentrations of ROS as subcellular microdomains generated by precise distributions and interplays between ROS-generating and ROS-degrading systems. In this regard, ROS signaling could be compared with intracellular Ca 2ϩ signaling, where specific Ca 2ϩ microdomains are responsible for the multiple regulating actions of this second messenger (12, 35, 49) . Probably, as has been the case with Ca 2ϩ , new methodological developments will allow simultaneous measurements of general redox status of the cell (e.g., GSH/GSSG levels, cellular ROS levels with current fluorescence indicators) along with that of specific subcellular compartments to truly understand the importance of ROS in the activation (or inhibition) of specific cellular functions (44) .
